Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Behav Sci Law. 2022 Mar;40(2):331-350. doi: 10.1002/bsl.2576. Epub 2022 May 16.
Individuals with borderline personality disorder (BPD) or antisocial personality disorder (ASPD) are overrepresented in forensic settings. Yet, despite the burden these disorders place on healthcare and criminal justice systems, there remains a lack of evidence-based pharmacological treatments. Epidemiological data have shown that comorbid cannabis use disorders are common in BPD and ASPD. ∆ -Tetrahydrocannabinol, the primary psychoactive constituent of cannabis, is an exogenous cannabinoid that stimulates the endocannabinoid system (ECS). Hence, an investigation of the ECS in these conditions is warranted. This scoping review screened 105 records and summarized the extant research on the ECS in ASPD (n = 69) and BPD (n = 61) participants. Preliminary results suggest that alterations of the ECS may be present in these disorders. Although research examining the ECS in personality disorders is still in its infancy, more research is warranted given initial positive findings.
个体患有边缘型人格障碍(BPD)或反社会型人格障碍(ASPD)在法医环境中人数过多。尽管这些疾病给医疗保健和刑事司法系统带来了负担,但仍然缺乏基于证据的药物治疗方法。流行病学数据显示,合并使用大麻的疾病在 BPD 和 ASPD 中很常见。大麻的主要精神活性成分 ∆ -四氢大麻酚是一种外源性大麻素,可刺激内源性大麻素系统(ECS)。因此,有必要对这些情况下的 ECS 进行调查。这项范围审查筛选了 105 份记录,并总结了关于 ECS 在 ASPD(n=69)和 BPD(n=61)参与者中的现有研究。初步结果表明,这些疾病中可能存在 ECS 的改变。尽管研究人格障碍中的 ECS 仍处于起步阶段,但鉴于最初的积极发现,需要进行更多的研究。